Royal Bank Of Canada Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM) had its price target increased by Royal Bank Of Canada from $283.00 to $322.00 in a research report sent to investors on Thursday,Benzinga reports. Royal Bank Of Canada currently has an outperform rating on the insurance provider’s stock.

A number of other analysts have also weighed in on HUM. Bank of America lowered their target price on Humana from $320.00 to $260.00 and set a “neutral” rating for the company in a research note on Tuesday, June 17th. Cantor Fitzgerald restated a “neutral” rating and issued a $290.00 target price on shares of Humana in a research note on Thursday, May 1st. Oppenheimer lifted their price objective on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a research report on Thursday, May 1st. Raymond James Financial upgraded Humana from a “market perform” rating to an “outperform” rating and set a $315.00 price objective for the company in a research report on Thursday, May 1st. Finally, Wells Fargo & Company lowered their price objective on Humana from $348.00 to $344.00 and set an “overweight” rating for the company in a research report on Thursday, August 14th. Seven investment analysts have rated the stock with a Buy rating and sixteen have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $283.29.

Humana Stock Performance

Shares of NYSE:HUM opened at $294.2280 on Thursday. Humana has a twelve month low of $206.87 and a twelve month high of $382.72. The firm has a market cap of $35.39 billion, a PE ratio of 22.58, a price-to-earnings-growth ratio of 1.71 and a beta of 0.44. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.95 and a current ratio of 1.95. The business has a fifty day moving average of $247.28 and a 200-day moving average of $253.70.

Humana (NYSE:HUM) last announced its earnings results on Wednesday, July 30th. The insurance provider reported $6.27 earnings per share for the quarter, missing analysts’ consensus estimates of $6.32 by ($0.05). Humana had a net margin of 1.28% and a return on equity of 13.67%. The business had revenue of $32.39 billion during the quarter, compared to analyst estimates of $31.85 billion. During the same quarter last year, the business posted $6.96 earnings per share. The business’s quarterly revenue was up 9.6% compared to the same quarter last year. Humana has set its FY 2025 guidance at 17.000- EPS. On average, equities research analysts predict that Humana will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Friday, September 26th will be given a dividend of $0.885 per share. This represents a $3.54 annualized dividend and a dividend yield of 1.2%. Humana’s payout ratio is currently 27.17%.

Hedge Funds Weigh In On Humana

Institutional investors have recently modified their holdings of the stock. Cary Street Partners Investment Advisory LLC grew its position in shares of Humana by 63.9% during the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after buying an additional 46 shares during the period. Elevation Point Wealth Partners LLC acquired a new position in shares of Humana during the 2nd quarter worth about $32,000. Riverview Trust Co acquired a new position in shares of Humana during the 1st quarter worth about $34,000. Garde Capital Inc. acquired a new position in shares of Humana during the 1st quarter worth about $36,000. Finally, Zions Bancorporation National Association UT acquired a new position in shares of Humana during the 1st quarter worth about $37,000. 92.38% of the stock is currently owned by institutional investors and hedge funds.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.